• Je něco špatně v tomto záznamu ?

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

RT. Penson, RV. Valencia, D. Cibula, N. Colombo, CA. Leath, M. Bidziński, JW. Kim, JH. Nam, R. Madry, C. Hernández, PAR. Mora, SY. Ryu, T. Milenkova, ES. Lowe, L. Barker, G. Scambia,

. 2020 ; 38 (11) : 1164-1174. [pub] 20200219

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028268

PURPOSE: A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial (SOLO3) of olaparib tablets versus nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy. PATIENTS AND METHODS: In this randomized, open-label trial, patients were randomly assigned 2:1 to olaparib 300 mg twice a day or physician's choice single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan). The primary end point was objective response rate (ORR) in the measurable disease analysis set assessed by blinded independent central review (BICR). The key secondary end point was progression-free survival (PFS) assessed by BICR in the intent-to-treat population. RESULTS: Of 266 randomly assigned patients, 178 were assigned to olaparib and 88 to chemotherapy. In patients with measurable disease (olaparib, n = 151; chemotherapy, n = 72), the BICR-assessed ORR was significantly higher with olaparib than with chemotherapy (72.2% v 51.4%; odds ratio [OR], 2.53 [95% CI, 1.40 to 4.58]; P = .002). In the subgroup who had received 2 prior lines of treatment, the ORR was 84.6% with olaparib and 61.5% with chemotherapy (OR, 3.44 [95% CI, 1.42 to 8.54]). BICR-assessed PFS also significantly favored olaparib versus chemotherapy (hazard ratio, 0.62 [95% CI, 0.43 to 0.91]; P = .013; median, 13.4 v 9.2 months). Adverse events were consistent with the established safety profiles of olaparib and chemotherapy. CONCLUSION: Olaparib resulted in statistically significant and clinically relevant improvements in ORR and PFS compared with nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028268
003      
CZ-PrNML
005      
20210114153358.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.02745 $2 doi
035    __
$a (PubMed)32073956
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Penson, Richard T $u Harvard Medical School and Massachusetts General Hospital, Boston, MA.
245    10
$a Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial / $c RT. Penson, RV. Valencia, D. Cibula, N. Colombo, CA. Leath, M. Bidziński, JW. Kim, JH. Nam, R. Madry, C. Hernández, PAR. Mora, SY. Ryu, T. Milenkova, ES. Lowe, L. Barker, G. Scambia,
520    9_
$a PURPOSE: A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial (SOLO3) of olaparib tablets versus nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy. PATIENTS AND METHODS: In this randomized, open-label trial, patients were randomly assigned 2:1 to olaparib 300 mg twice a day or physician's choice single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan). The primary end point was objective response rate (ORR) in the measurable disease analysis set assessed by blinded independent central review (BICR). The key secondary end point was progression-free survival (PFS) assessed by BICR in the intent-to-treat population. RESULTS: Of 266 randomly assigned patients, 178 were assigned to olaparib and 88 to chemotherapy. In patients with measurable disease (olaparib, n = 151; chemotherapy, n = 72), the BICR-assessed ORR was significantly higher with olaparib than with chemotherapy (72.2% v 51.4%; odds ratio [OR], 2.53 [95% CI, 1.40 to 4.58]; P = .002). In the subgroup who had received 2 prior lines of treatment, the ORR was 84.6% with olaparib and 61.5% with chemotherapy (OR, 3.44 [95% CI, 1.42 to 8.54]). BICR-assessed PFS also significantly favored olaparib versus chemotherapy (hazard ratio, 0.62 [95% CI, 0.43 to 0.91]; P = .013; median, 13.4 v 9.2 months). Adverse events were consistent with the established safety profiles of olaparib and chemotherapy. CONCLUSION: Olaparib resulted in statistically significant and clinically relevant improvements in ORR and PFS compared with nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a ženské pohlaví $7 D005260
650    12
$a geny BRCA1 $7 D019398
650    12
$a geny BRCA2 $7 D024522
650    12
$a zárodečné mutace $7 D018095
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a nádory vaječníků $x farmakoterapie $x genetika $x mortalita $7 D010051
650    _2
$a ftalaziny $x škodlivé účinky $x terapeutické užití $7 D010793
650    _2
$a piperaziny $x škodlivé účinky $x terapeutické užití $7 D010879
650    _2
$a sloučeniny platiny $x terapeutické užití $7 D017671
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Valencia, Ricardo Villalobos $u Centro Medico Dalinde, Mexico City, Mexico.
700    1_
$a Cibula, David $u First Faculty of Medicine, Charles University and General University, Prague, Czech Republic.
700    1_
$a Colombo, Nicoletta $u University of Milan-Bicocca and IEO European Institute of Oncology IRCCS, Milan, Italy.
700    1_
$a Leath, Charles A $u University of Alabama, Birmingham, AL.
700    1_
$a Bidziński, Mariusz $u Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland.
700    1_
$a Kim, Jae-Weon $u Seoul National University Hospital, Seoul, South Korea.
700    1_
$a Nam, Joo Hyun $u Asan Medical Center, Seoul, South Korea.
700    1_
$a Madry, Radoslaw $u Medical University K. Marcinkowski and Clinical Hospital of the Transfiguration, Poznań, Poland.
700    1_
$a Hernández, Carlos $u Oaxaca Site Management Organization, Oaxaca de Juarez, Mexico.
700    1_
$a Mora, Paulo A R $u Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil.
700    1_
$a Ryu, Sang Young $u Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
700    1_
$a Milenkova, Tsveta $u AstraZeneca, Cambridge, United Kingdom.
700    1_
$a Lowe, Elizabeth S $u AstraZeneca, Gaithersburg, MD.
700    1_
$a Barker, Laura $u AstraZeneca, Cambridge, United Kingdom.
700    1_
$a Scambia, Giovanni $u Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 38, č. 11 (2020), s. 1164-1174
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32073956 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153355 $b ABA008
999    __
$a ok $b bmc $g 1608603 $s 1119448
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 11 $d 1164-1174 $e 20200219 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace